N2OFF (NITO) provides $372K bridge loan to MitoCareX Bio pending acquisition

Nexentis Technologies Inc.

Loan principal $372,000 from N2OFF to MitoCareX Bio Ltd., term 6 months, interest at Israel Tax Authority USD rate +3%.
Disbursement in three tranches: $200K at signing, $86K on Sep 15, 2025, $86K on Oct 15, 2025.
L.I.A. Pure Capital Ltd. guarantees full repayment of principal and interest.
If acquisition closes, outstanding loan amount deducted from first-year allocation to MitoCareX.
Loan supports MitoCareX's ongoing costs until acquisition stockholder approval and closing.

item 1.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.